Hasegawa, Kosei http://orcid.org/0000-0002-1903-7001
Kagabu, Masahiro
Mizuno, Mika
Oda, Katsutoshi
Aoki, Daisuke
Mabuchi, Seiji
Kamiura, Shoji
Yamaguchi, Satoshi
Aoki, Yoichi
Saito, Toshiaki
Yunokawa, Mayu
Takehara, Kazuhiro
Okamoto, Aikou
Ochiai, Kazunori
Kimura, Tadashi
Article History
Received: 11 June 2017
Accepted: 17 August 2017
First Online: 2 September 2017
Compliance with ethical standards
:
: Kosei Hasegawa reports other from Yakult Honsha Co., Ltd., other from Ono Pharmaceutical Co., Ltd., other from Taiho Pharmaceutical Co., Ltd., other from Kyowa Hakko Kirin Co., Ltd., other from Chugai Pharmaceutical Co., Ltd., outside the submitted work; Daisuke Aoki reports grants from Chugai Pharmaceutical Co., Ltd., grants from Taiho Pharmaceutical Co., Ltd., personal fees from MSD K.K., personal fees from AstraZeneca K.K., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from GlaxoSmithKline K.K., personal fees from Daiichi Sankyo Co., Ltd., personal fees from Taiho Pharmaceutical Co., Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Nippon Kayaku Co., Ltd., personal fees from Becton, Dickinson and Company, personal fees from Novartis Pharma K.K., personal fees from Bristol-Myers K.K., personal fees from Janssen Pharmaceutical K.K., personal fees from Roche Diagnostics K.K., personal fees from Yakult Honsha Co., Ltd., outside the submitted work; Mayu Yunokawa reports grants from Yakult Honsha Co., Ltd., outside the submitted work; Kazunori Ochiai reports grants from Taiho Pharmaceutical Co., Ltd., grants from Zeria Pharmaceutical Co., Ltd., outside the submitted work; Tadashi Kimura reports personal fees from Yakult Honsha Co., Ltd., outside the submitted work; All other authors have no conflicts of interest to declare.
: The protocol was approved by the ethics committee of each participating institution. The trial was conducted in compliance with the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines.
: Written informed consent for inclusion, including in the biomarker analysis, was obtained from all patients prior to registration.